| If you appreciate this station please support it with your generous donation. Your PayPal donation below will help keep this venue available to the public. |
" It's Time for a New Paradigm."
"AKERU" - Kemetic term for retrieving ancient wisdom from the past for today's success.
Drawing on the old to wisely create the new.
AKERU Global Network is our world community's Internet gateway to
unification and enlightenment, providing the refined, earnest, earthy quality of
public radio/TV from a counter culture global perspective.
Promoting "Global Thinking, Local Action".
AKERU Radio presents the best of world public radio. World music, news,
lectures, historical speeches, cultural conversations, life empowerment
shows, radio documentaries. Educational conversations on politics,
metaphysics, holistic health, environmentalism, animal activism, alternative
spirituality.
AKERU TV brings live, streaming, and on-demand viewing with cultural
shows, DIY, green living, activism, metaphysics, positive art, music, vegan
cooking, and history videos.
AKERU Global Network's founder/engineer is Imakhu Mwt Shekemet.
"Your Global Unification Station"
"Leading the Way in the Global Consciousness Movement."
"It's Time for a New Paradigm."
"AKERU" - Kemetic term for retrieving ancient wisdom from the past for today's success.
Drawing on the old to wisely create the new.
AKERU Global Network is our world community's Internet gateway to
unification and enlightenment, providing the refined, earnest, earthy quality of
public radio/TV from a counter culture global perspective.
Promoting "Global Thinking, Local Action".
AKERU Radio presents the best of world public radio. World music, news,
lectures, historical speeches, cultural conversations, life empowerment
shows, radio documentaries. Educational conversations on politics,
metaphysics, holistic health, environmentalism, animal activism, alternative
spirituality.
AKERU TV brings live, streaming, and on-demand viewing with cultural
shows, DIY, green living, activism, metaphysics, positive art, music, vegan
cooking, and history videos.
AKERU Global Network's founder/engineer is Imakhu Mwt Shekemet.
"Your Global Unification Station"
"Leading the Way in the Global Consciousness Movement."
"It's Time for a New Paradigm."
To become an ongoing
AKERU supporter please
subscribe for $5 a month.
AKERU supporter please
subscribe for $5 a month.
To become a station
sponsor, please
subscribe at $15 a
month. Your
name/business will
be listed and linked
on the station
webpage.
sponsor, please
subscribe at $15 a
month. Your
name/business will
be listed and linked
on the station
webpage.
Become an advertiser
on this site
Call 646-713-8650
imakhu@akeruradio.com
on this site
Call 646-713-8650
imakhu@akeruradio.com
AKERU Global Network
CEE LEE PRODUCTIONS
Internet Website Development
www.art-alive.com/design
design@art-alive.com
212-666-0304
CEE LEE'S GALLERIA
Boutique Shopping on the Internet
www.CeeLee.com
Internet Website Development
www.art-alive.com/design
design@art-alive.com
212-666-0304
CEE LEE'S GALLERIA
Boutique Shopping on the Internet
www.CeeLee.com
Not listening to
AKERU Radio?
AKERU Radio?
 |
 |
 |
 |
 |
 |
 |
Queen Mother Imakhu's
COWRIE BLESSINGS BOOK
for Conscious Spiritual Living
from a NuAfrakan,
metaphysical point of view
COWRIE BLESSINGS BOOK
for Conscious Spiritual Living
from a NuAfrakan,
metaphysical point of view
To receive your FREE mp3 download, "Creating Positive Community" by Imakhu, describe your favorite part of the
AKERU Global Network broadcast in the request form below!
AKERU Global Network broadcast in the request form below!
"Be Healthy....Actually"
BROWN EYEZ MAGAZINE
P.J., CEO
Phone: 973-493-3436
BROWN EYEZ MAGAZINE
P.J., CEO
Phone: 973-493-3436
Herbert Harris, Author of
TWELVE UNIVERSAL
LAWS OF SUCCESS
www.lifeskillinstitute.org
lifeskill@eathlink.net
800-570-4009
TWELVE UNIVERSAL
LAWS OF SUCCESS
www.lifeskillinstitute.org
lifeskill@eathlink.net
800-570-4009
HEALTHEE ENDEAVORS
Powerful traditional Jamaican
herbal remedies to cleanse and
regulate the body systems.
3565 Boston Rd, Bronx, NY.
718-653-4140
Powerful traditional Jamaican
herbal remedies to cleanse and
regulate the body systems.
3565 Boston Rd, Bronx, NY.
718-653-4140
AKERU Global Network
Advertise with the $25
month bonus
package: A daily ad
played on AKERU
Radio, Print ad on
AKERU Radio &
AKERU TV web
pages!
month bonus
package: A daily ad
played on AKERU
Radio, Print ad on
AKERU Radio &
AKERU TV web
pages!
God-S Wearable Art
Designed to celebrate the
Nubian God-S in you!
www.on-que.com
Designed to celebrate the
Nubian God-S in you!
www.on-que.com
What's the Latest News on GARDASIL?
| Akeru radio is now heard on ubroadcast.com! Better quality, no more annoying live 365 ads! more interactive listener options! Press the button below to open the station player. bookmark as favorite for easy listening! |
| AKERU TV is now broadcasting LIVE topical programming! Includes: Living Green, Vegan Cooking, Holistic Health, Social Justice, Activism, World Music, Politics! |
Sis. Karen Hatter is the featured social commentator for AKERU Global Radio and the TV show "ASHE!".
She is also a regularly featured columnist and guest editor at Now Public.com.
She is also a regularly featured columnist and guest editor at Now Public.com.
On June 25, 2008, the Food and Drug Administration (FDA) denied approval
of GARDASIL for use in women between the ages of 27 and 45.
of GARDASIL for use in women between the ages of 27 and 45.
The drug, manufactured by Merck & Co., has been heralded as the leading vaccine in targeting
and preventing the growth of four strains of human papilloma viruses (HPV), two of which have
been said to cause cervical cancer.
Human papilloma viruses, more commonly called HPVs, are numerous genotypes causing
various human warts, like the common warts found on hands and feet, plantar warts, and genital
warts, including some 15 known strains associated with the production of cervical cancer.
Makers of the drug and its proponents have been claiming GARDASIL prevents cervical
cancer, an unsubstantiated claim as girls and women involved in initial drug trials, who numbered
less than 30,000, were not tracked until the usual age of the onset of cervical cancer, which
occurs between the ages of 35 to 45. The average length of follow up study was less than five
years.
In April 2006, according to a PharmaceuticalOnline.com article, Merck & Co. Inc., a self
professed global research-driven pharmaceutical company under new leadership, proclaimed
itself, among other things, ”...(the company) that investors can look to first for growth among
pharmaceutical companies...”, relying heavily on its new line of vaccine products to produce
much of that forecast growth.
In June 2006, GARDASIL was approved by the FDA for use in girls ages 9 through women
aged 26. The drug is currently being marketed worldwide with GARDASIL, during one of its first
quarters, according to Bloomberg.com, netting $390 million.
In my second article posted here at NowPublic, published more than a year ago, writing
about the marketing of GARDASIL in my piece entitled, Creating a Market for and Testing HPV
Vaccines, I began with a quote from the American Cancer Society web site:
Seventy percent (70%) of human papilloma virus (HPV) infections are typically gone within
one year and 90% are gone within 2 years.
Also stated at the web site:
Most people will never know if they have HPV because no significant disease develops and
the immune system suppresses the virus. A small percent of people with HPV will have the virus
for a longer time and will develop cell changes that may lead over many years to cervical or
other anogenital cancer.
From the National Cancer Institute, found at cancer.gov, it states:
Are there specific types of HPV that are associated with cancer?
Some types of HPV are referred to as “low-risk” viruses because they rarely cause
lesions that develop into cancer. HPV types that are more likely to lead to the development of
cancer are referred to as “high-risk.” Both high-risk and low-risk types of HPV can cause the
growth of abnormal cells, but only the high-risk types of HPV lead to cancer. Sexually
transmitted, high-risk HPVs include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and
73 (4). These high-risk types of HPV cause growths on the cervix that are usually flat and nearly
invisible, as compared with the external warts caused by low-risk types HPV–6 and HPV–11.
HPV types 16 and 18 together cause about 70 percent of cervical cancers (4, 5). It is important to
note, however, that the great majority of high-risk HPV infections go away on their own and do
not cause cancer (5). GARDASIL targets four HPV strains, two of which, HPV 16 and 18, are
being identified above as being responsible for 70% of cervical cancers.
Concerns have been raised by physicians noting the possibility that vaccination against two of
fifteen known HPV strains linked to cancer may result in other strains becoming more aggressive.
According to this article, cervical cancer among the age groups of girls and women in the
United States being vaccinated with GARDASIL, girls and women between the ages of 9 and 26, is
rare, with approximately 3 to 4 cases per 100,000 or 30 to 40 cases of cervical cancer per 1
million girls and women or .00003% to .00004% ( 3 to 4 hundred thousandths of one percent)
reported in that age category.
Until a thoroughly independent study of this and all future HPV vaccines is commissioned
and completed, which has not occurred to date, it is merely healthy skepticism to seek more
information on a product when the company that is responsible for all of the good and glowing
news regarding the product is the only resource from which everyone else is getting their
information.
It has been reported, Merck settled some 27,000 claims, representing 47,000 claimants and
265 possible class action lawsuits related to allegations of death and injuries by Vioxx, three
years after removing the drug from market, for $4.85 billion.
Merck & Co. credits the sale of GARDASIL with helping to reclaim monetary losses that
occurred after damages and loss of life that appeared to be linked to the use of Vioxx, which
resulted in one of the largest monetary awards for settlement of claims resulting from the drug's
use.
As of June 23, 2008, Merck & Co. is in the process of a appealing a suit concerning Vioxx,
filed in Missouri.
My first article at NowPublic, Public Health or Profit? What Drives the HPV Vaccination
Campaign?, highlighted sets of circumstances that surrounded the timing and introduction of
GARDASIL onto the drug market.
Merck & Co. predicts this recent refusal by the FDA will slow earlier projected profits
anticipated to result from the approval and expansion of the age groups for the use of GARDASIL
among women.
The public must come to understand that FDA approval doesn't mean a drug is not without
it's dangers.
and preventing the growth of four strains of human papilloma viruses (HPV), two of which have
been said to cause cervical cancer.
Human papilloma viruses, more commonly called HPVs, are numerous genotypes causing
various human warts, like the common warts found on hands and feet, plantar warts, and genital
warts, including some 15 known strains associated with the production of cervical cancer.
Makers of the drug and its proponents have been claiming GARDASIL prevents cervical
cancer, an unsubstantiated claim as girls and women involved in initial drug trials, who numbered
less than 30,000, were not tracked until the usual age of the onset of cervical cancer, which
occurs between the ages of 35 to 45. The average length of follow up study was less than five
years.
In April 2006, according to a PharmaceuticalOnline.com article, Merck & Co. Inc., a self
professed global research-driven pharmaceutical company under new leadership, proclaimed
itself, among other things, ”...(the company) that investors can look to first for growth among
pharmaceutical companies...”, relying heavily on its new line of vaccine products to produce
much of that forecast growth.
In June 2006, GARDASIL was approved by the FDA for use in girls ages 9 through women
aged 26. The drug is currently being marketed worldwide with GARDASIL, during one of its first
quarters, according to Bloomberg.com, netting $390 million.
In my second article posted here at NowPublic, published more than a year ago, writing
about the marketing of GARDASIL in my piece entitled, Creating a Market for and Testing HPV
Vaccines, I began with a quote from the American Cancer Society web site:
Seventy percent (70%) of human papilloma virus (HPV) infections are typically gone within
one year and 90% are gone within 2 years.
Also stated at the web site:
Most people will never know if they have HPV because no significant disease develops and
the immune system suppresses the virus. A small percent of people with HPV will have the virus
for a longer time and will develop cell changes that may lead over many years to cervical or
other anogenital cancer.
From the National Cancer Institute, found at cancer.gov, it states:
Are there specific types of HPV that are associated with cancer?
Some types of HPV are referred to as “low-risk” viruses because they rarely cause
lesions that develop into cancer. HPV types that are more likely to lead to the development of
cancer are referred to as “high-risk.” Both high-risk and low-risk types of HPV can cause the
growth of abnormal cells, but only the high-risk types of HPV lead to cancer. Sexually
transmitted, high-risk HPVs include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and
73 (4). These high-risk types of HPV cause growths on the cervix that are usually flat and nearly
invisible, as compared with the external warts caused by low-risk types HPV–6 and HPV–11.
HPV types 16 and 18 together cause about 70 percent of cervical cancers (4, 5). It is important to
note, however, that the great majority of high-risk HPV infections go away on their own and do
not cause cancer (5). GARDASIL targets four HPV strains, two of which, HPV 16 and 18, are
being identified above as being responsible for 70% of cervical cancers.
Concerns have been raised by physicians noting the possibility that vaccination against two of
fifteen known HPV strains linked to cancer may result in other strains becoming more aggressive.
According to this article, cervical cancer among the age groups of girls and women in the
United States being vaccinated with GARDASIL, girls and women between the ages of 9 and 26, is
rare, with approximately 3 to 4 cases per 100,000 or 30 to 40 cases of cervical cancer per 1
million girls and women or .00003% to .00004% ( 3 to 4 hundred thousandths of one percent)
reported in that age category.
Until a thoroughly independent study of this and all future HPV vaccines is commissioned
and completed, which has not occurred to date, it is merely healthy skepticism to seek more
information on a product when the company that is responsible for all of the good and glowing
news regarding the product is the only resource from which everyone else is getting their
information.
It has been reported, Merck settled some 27,000 claims, representing 47,000 claimants and
265 possible class action lawsuits related to allegations of death and injuries by Vioxx, three
years after removing the drug from market, for $4.85 billion.
Merck & Co. credits the sale of GARDASIL with helping to reclaim monetary losses that
occurred after damages and loss of life that appeared to be linked to the use of Vioxx, which
resulted in one of the largest monetary awards for settlement of claims resulting from the drug's
use.
As of June 23, 2008, Merck & Co. is in the process of a appealing a suit concerning Vioxx,
filed in Missouri.
My first article at NowPublic, Public Health or Profit? What Drives the HPV Vaccination
Campaign?, highlighted sets of circumstances that surrounded the timing and introduction of
GARDASIL onto the drug market.
Merck & Co. predicts this recent refusal by the FDA will slow earlier projected profits
anticipated to result from the approval and expansion of the age groups for the use of GARDASIL
among women.
The public must come to understand that FDA approval doesn't mean a drug is not without
it's dangers.
